| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
866,060 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
55,541 |
485,736 |
| Total Sell Value |
$0 |
$0 |
$11,412,520 |
$88,282,436 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
19 |
71 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Romp Charles R |
EVP, Commercial |
• – – |
2020-11-04 |
4 |
S |
$178.63 |
$2,539,420 |
D/D |
(14,079) |
44,077 |
|
17% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-11-04 |
4 |
OE |
$31.37 |
$587,703 |
D/D |
14,079 |
45,295 |
|
- |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-11-04 |
4 |
S |
$177.00 |
$1,356,020 |
D/D |
(7,661) |
110,221 |
|
17% |
|
| Lippman Marc E |
Director |
– • – |
2020-11-03 |
4 |
S |
$167.10 |
$23,958,287 |
D/D |
(142,090) |
52,338 |
|
13% |
|
| Lippman Marc E |
Director |
– • – |
2020-11-03 |
4 |
OE |
$20.06 |
$2,226,870 |
D/D |
62,780 |
144,432 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-11-03 |
4 |
S |
$169.51 |
$1,042,939 |
D/D |
(6,061) |
44,077 |
|
13% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-11-03 |
4 |
OE |
$15.46 |
$99,979 |
D/D |
5,197 |
47,719 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-11-02 |
4 |
S |
$166.00 |
$2,168,129 |
D/D |
(13,001) |
44,941 |
|
10% |
|
| Welch Daniel G |
Director |
– • – |
2020-11-02 |
4 |
S |
$164.61 |
$9,760,260 |
D/D |
(58,750) |
47,348 |
|
10% |
|
| Welch Daniel G |
Director |
– • – |
2020-11-02 |
4 |
OE |
$19.02 |
$1,247,653 |
D/D |
49,500 |
71,098 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2020-09-21 |
4 |
OE |
$35.95 |
$366,019 |
D/D |
9,954 |
58,642 |
|
- |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2020-09-14 |
4 |
AS |
$170.00 |
$1,973,700 |
D/D |
(11,610) |
48,688 |
|
0% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-09-09 |
4 |
AS |
$146.73 |
$1,180,385 |
D/D |
(8,000) |
186,829 |
|
25% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-09-09 |
4 |
OE |
$15.46 |
$123,680 |
D/D |
8,000 |
194,829 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-09-01 |
4 |
AS |
$155.25 |
$1,884,512 |
D/D |
(12,091) |
126,276 |
|
15% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2020-08-31 |
4 |
AS |
$155.69 |
$651,892 |
D/D |
(4,187) |
138,367 |
|
14% |
|
| Liu Jean I |
GC/EVP, Leg Affairs |
• – – |
2020-08-31 |
4 |
AS |
$155.69 |
$567,972 |
D/D |
(3,648) |
60,298 |
|
14% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-08-31 |
4 |
AS |
$155.69 |
$176,402 |
D/D |
(1,133) |
57,942 |
|
14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-31 |
4 |
AS |
$155.69 |
$2,234,367 |
D/D |
(14,351) |
715,209 |
|
14% |
|
| Dansey Roger D |
Chief Medical Officer |
• – – |
2020-08-31 |
4 |
AS |
$155.69 |
$717,906 |
D/D |
(4,611) |
117,882 |
|
14% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-08-31 |
4 |
AS |
$155.69 |
$558,164 |
D/D |
(3,585) |
186,829 |
|
14% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-21 |
4 |
OE |
$15.46 |
$199,984 |
D/D |
10,299 |
729,560 |
|
- |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2020-08-18 |
4 |
AS |
$158.17 |
$636,941 |
D/D |
(4,027) |
59,075 |
|
17% |
|
| Siegall Clay B |
President and CEO |
• • – |
2020-08-18 |
4 |
AS |
$158.17 |
$4,280,053 |
D/D |
(27,060) |
719,261 |
|
17% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2020-08-18 |
4 |
AS |
$158.17 |
$1,273,892 |
D/D |
(8,054) |
190,414 |
|
17% |
|
952 Records found
|
|
Page 14 of 39 |
|
|
